Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (745)	9/18/2007 4:07:39 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Yes, ad-MDA7 combo has shown enhanced tumor killing activity.<g> The combo with Velcade is just another unknown synergistic effect, or has it indeed been demostrated that is dependent on the slowdown of the MDA-7/IL-24 ubiquitination and degradation by the 26S proteasome ? Here are a few links to previous "combos": ad-MDA7 can work synergistically with inhibitors of epidermal growth factor receptors, such as Erbitux, Vectibix, Tarceva and Iressa Message 22974581 ad-MDA-7 in combo with Avastin Message 22231894 The MDA7-Avastin mice studies.. Message 23224001 Ad-MDA7 and the benzoquinone ansamycin geldanamycin (GA) interact in a highly synergistic manner to induce cell death in human lung cancer cells. Message 22889428 Treatment of subcutaneous lung tumor xenografts with bevacizumab plus Ad-MDA7 resulted in significant tumor growth inhibition and improved survival Message 23215514 Geldanamycin or 17AAG can overcome Ad-MDA7 resistance in an established in vitro model. Message 23371222 Injecting Ad.PEG-E1A-mda-7 into xenografts derived from Du-145-Bcl-xL cells in athymic nude mice completely eradicated not only the primary tumor but also distant tumors. (obliterating prostate cancer cells by enhancing it with the PEG-3 promoter to amplify MDA7 production that overcame Bcl related resistance to therapy.) Message 23450250 Ad-MDA7 induced activation of not only PKR, but also AKT in human lung cancer cells. Adenoviral mediated overexpression of mda-7 (Ad-MDA7) leads to a rapid induction and activation of PKR, which correlates with apoptosis in A549 and H1299 human lung cancer cells. Ad-MDA7 induced activation of not only PKR, but also AKT in these cells. Growth factors and oncogene products affect enzymes in the phosphatidylinositol (PI) signal transduction pathways. The middle T protein of a DNA tumor virus, polyoma virus, forms a complex with a cellular PI kinase. This enzyme is also activated by almost all growth factors that act through receptor protein-tyrosine kinases (several of which are proto-oncogenes). Activation of this pathway is essential for the ability of cells to grow in response to several growth factors. These results strongly implicate this enzyme in growth and transformation pathways. The oncoprotein-associated PI kinase is in a pathway distinct from the conventional hormone-responsive turnover of PI in response to hormones. In conventional turnover PI is phosphorylated in the D-4 position of the inositol ring to produce PI-4-phosphate, followed by a second phosphorylation to form PI-4,5-biphosphate, the precursor for the two second messengers: inositol-1,4,5-trisphosphate and diacylglycerol. In contrast, the discovered oncoprotein-associated PI kinase phosphorylates the D-3 position on the inositol ring to produce PI-3-phosphate. This PI-3-phosphate production is the first step in a pathway that provides a signal for growth and that certain oncogenes accomplish cell transformation by overstimulating this pathway. Message 22231838 And INGN has a patent for the systemic delivery of tumor suppressor genes such as p53, mda-7 and numerous others, by using synthetic nanoparticles,which protects Introgen's non-viral delivery platform. Message 23032419 Bernard